Business Context and Reporting Period
This Form 8-K Current Report was filed by Genprex, Inc. on January 7, 2026. The filing primarily serves to disclose Regulation FD information regarding a corporate investor presentation and to announce significant clinical program updates for the Company's diabetes gene therapy candidate, GPX-002.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on operational milestones and regulatory strategy rather than financial performance.
Material Changes and Operational Milestones
Genprex reported several material advancements in its GPX-002 program during 2025 and early 2026:
- Research Expansion: Commenced preclinical studies in Type 2 diabetic (T2D) animal models, expanding beyond Type 1 diabetes (T1D). Preliminary data showed GPX-002 rejuvenated exhausted beta cells and normalized glucose levels in T2D models.
- Regulatory Engagement: Submitted a request to the U.S. Food and Drug Administration (FDA) for a meeting scheduled for the first quarter of 2026 to discuss Investigational New Drug (IND)-enabling studies.
- Technology Transfer: Successfully transferred the manufacturing process for GPX-002 from academic collaborators to an experienced network of contract development and manufacturing organizations (CDMOs).
Outlook, Management Commentary, and Risks
Future Steps and Strategy:
- Manufacturing Scale-Up: Plans to begin clinical-scale production in a current Good Manufacturing Practices (cGMP) compliant facility to accelerate IND-enabling studies.
- Product Optimization: Continuing work to optimize constructs and evaluating a second-generation non-viral lipid nanoparticle delivery system.
- Toxicology Studies: Following the FDA meeting, the Company will finalize and initiate toxicology studies required for IND filing.
Risks and Contingencies:
The filing includes extensive forward-looking statements cautioning that actual results may differ materially from expectations. Key risks include:
- Ability to advance clinical development and manufacturing according to projected timelines.
- Success of the upcoming FDA meeting and subsequent toxicology studies.
- Ability to regain and maintain compliance with Nasdaq Capital Market listing requirements.
- Continuing as a going concern and obtaining necessary capital to meet long-term liquidity needs.
Investor Verification Checklist
- Verify the date and agenda of the scheduled FDA meeting in Q1 2026.
- Review the Company's most recent Form 10-K for details on liquidity, cash runway, and Nasdaq compliance status.
- Monitor the timeline for the initiation of toxicology studies following the FDA interaction.
- Assess the progress of the technology transfer to CDMOs and the readiness of cGMP facilities for clinical scale-up.
- Examine the preliminary preclinical data for GPX-002 in T2D models referenced in the press release.